CARSO Group has acquired Bactéries et Aliments
CARSO Group has strengthened its leadership in the food safety sector through the acquisition of Bactéries et Aliments.
Established in 1992 and headquartered in France, CARSO is one of the leading providers of analytical services in the French market, with operations in several neighboring countries. The company offers a broad range of analyses, including water and environmental testing, occupational hygiene and building health, food safety, genetic testing and pharmaceutical analysis. In 2021, ARCHIMED became CARSO’s majority shareholder, in partnership with CAPZA, Siparex, the management team and the company’s founders. Since then, ARCHIMED has supported CARSO’s organic and external growth across Europe through targeted acquisitions and strategic partnerships in high-potential market segments. The shared objective is to further strengthen CARSO’s position as an independent, entrepreneurial and international platform in the analytical services industry.
Founded over 20 years ago, Bactéries et Aliments is a laboratory specializing in microbiological analysis. It is recognized in the field of food hygiene for its customized services, expert guidance and cutting-edge R&D activities that support development projects within the food industry.
Oaklins’ team in France advised CARSO and its shareholders on the acquisition of Bactéries et Aliments.
Falar com a equipa da transação
Transações relacionadas
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Saber maisMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Saber maisQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Saber mais